nasopharyngeal carcinoma
Conditions
Interventions
experimental group:Recombinant Human Thrombopoietin Combined with hetrombopag
Sponsors
zhejiang cancer hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1: Patients with newly histologically confirmed non-keratinizing (according to World Health Organization (WHO) histologically type). 2: Tumor staged as T3-4N1/N2-3 (according to the 8th American Joint Commission on Cancer edition). 3: No evidence of distant metastasis (M0). 4: Patients must be informed of the investigational nature of this study and give written informed consent. 5: Receiving induction chemotherapy and sequential synchronous radiochemotherapy 6: Satisfactory performance status: Karnofsky scale (KPS) > 70. Adequate marrow: leucocyte count =4000/µL, hemoglobin =90g/L and platelet count =100000/µL. Normal liver function test: Alanine Aminotransferase (ALT)Aspartate Aminotransferase (AST) <1.5×upper limit of normal (ULN) concomitant with alkaline phosphatase (ALP) =2.5×ULN, and bilirubin =ULN. Adequate renal function: creatinine clearance =60 ml/min. 7:Aged = 18 years and = 75 years 8:The Eastern Cooperative Oncology Group (ECOG) score: 0~1 point 9:Platelet < 50x10^9/L;
Exclusion criteria
Exclusion criteria: 1: WHO Type keratinizing squamous cell carcinoma or basaloid squamous cell carcinoma. 2: Treatment with palliative intent. Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer. 3: Pregnancy or lactation. History of previous radiotherapy (except for non-melanomatous skin cancers outside intended RT treatment volume). 4: Prior chemotherapy or surgery (except diagnostic) to primary tumor or nodes. Any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose >1.5×ULN), and emotional disturbance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| he proportion of subjects who were effective after a week of treatment with Herombopag Olamine Tabletsin and Recombinant Human Thrombopoietin was defined as having platelet values restored to >= 75x10^9/L; | — |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of patients whose platelet values recovered to >= 100x10^9/L after Herombopag Olamine Tabletsin therapy;Platelet infusion rate after Herombopag Olamine Tabletsin treatment;safety;The incidence of reduced cycle chemotherapy intensity due to thrombocytopenia (reduced or delayed chemotherapy); | — |
Countries
china
Contacts
Public Contactting jin
zhejiang cancer hospital
Outcome results
None listed